Register of
Medicinal Products

Product class: Authorized package
Medicinal product class: For human use
Package code: 1809187
Name of medicinal product: BAQSIMI
Active substances:
Estonian, English, Latin
ATC code: H04AA01
Dosage form: nasal powder in single-dose container
Route of administration: nasal use
Strengh: 3mg
Amount in package: 2TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Safety features: Yes
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Last imported to Estonia: Never imported to Estonia
Marketing authorization holder: Amphastar France Pharmaceuticals 
Marketing authorization number: EU/1/19/1406 
Marketing authorization issued on: December 16, 2019 
Marketing authorization expires on: December 18, 2024 
Marketing authorization procedure type: Centralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: March 18, 2024
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere